Tag:

Keryx Biopharmaceuticals

Latest Headlines

Latest Headlines

FDA warning dampens Keryx's parade for newly approved kidney drug

When the FDA came through with their expected approval for Keryx's ferric citrate (formerly Zerenex), a new treatment to deal with complications of kidney disease, on Friday, a label warning that the drug could wind up triggering iron overload dampened analysts' enthusiasm for this treatment considerably, with Keryx's stock price ending Friday down 5%.

Keryx touts its kidney drug with an FDA decision around the corner

Keryx Biopharmaceuticals' in-development Zerenex helped reduce dangerous buildups of phosphorus in patients on kidney dialysis, meeting its goals in a Phase III study as the company awaits final word from the FDA.

Keryx jumps as kidney drug impresses in PhII, promises wider label

Keryx Biopharmaceuticals' shares jumped nearly 20% Tuesday morning on news that its chronic kidney disease drug Zerenex cleared a Phase II trial on nondialysis-dependent patients, possibly setting the stage for a broader indication once the much-scrutinized drug is approved.

Report on potential NCE threat for Keryx crimps big stock gain

Keryx is finding it hard to hang on to the huge gains its shares made last week after investors responded enthusiastically to positive data from a Phase III study of the phosphorous-clearing drug Zerenex.

Venture firm preps $100M fund for late-stage life sciences investments

Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.

Keryx shares soar on upbeat PhIII results for CKD drug Zerenex

Shares of Keryx Biopharmaceuticals roared into the fast lane this morning, shooting ahead 46% on the news that its long-awaited Phase III study of its phosphate binder Zerenex had wrapped with positive top-line data among kidney dialysis patients. The news positioned the small-cap biotech for marketing applications in the U.S. and Europe.

Keryx, Aeterna shares crater on word of Phase III cancer study flop

Canada's Aeterna Zentaris put out the word this morning that perifosine flamed out in a late-stage cancer study conducted by its partner Keryx Biopharmaceuticals.

Keryx ($KERX) claims a front-line victory with PhIII Zerenex data

Keryx Biopharmaceuticals' ($KERX) phosphate-lowering drug Zerenex proved effective in a late-stage study, positioning the biotech to make a 2012 run at the market-leading therapy by offering dialysis

Keryx's shares rally on new orphan drug title for perifosine

Keryx Biopharmaceuticals says that its experimental late-stage cancer drug perifosine won its second orphan drug classification from the FDA, helping fuel a rally in its share price. Already dubbed

Keryx shares spike as cancer drug wins fast track

With a late-stage trial for the colorectal cancer drug KRX-0401 looming this quarter, Aeterna Zentaris and partner Keryx say they won fast-track status from the FDA for the program. Keryx shares